MX2019009382A - Anticuerpo anti-humano de anexina a1. - Google Patents
Anticuerpo anti-humano de anexina a1.Info
- Publication number
- MX2019009382A MX2019009382A MX2019009382A MX2019009382A MX2019009382A MX 2019009382 A MX2019009382 A MX 2019009382A MX 2019009382 A MX2019009382 A MX 2019009382A MX 2019009382 A MX2019009382 A MX 2019009382A MX 2019009382 A MX2019009382 A MX 2019009382A
- Authority
- MX
- Mexico
- Prior art keywords
- seq
- set forth
- sequence set
- sequence
- vlcdr1
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/087—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being an annexin, e.g. annexin V
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- Virology (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Psychiatry (AREA)
- Mycology (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Microbiology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1702091.8A GB201702091D0 (en) | 2017-02-08 | 2017-02-08 | Specific binding molecules |
| PCT/EP2018/053232 WO2018146230A1 (en) | 2017-02-08 | 2018-02-08 | Anti human annexin a1 antibody |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019009382A true MX2019009382A (es) | 2019-12-16 |
Family
ID=58462456
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019009382A MX2019009382A (es) | 2017-02-08 | 2018-02-08 | Anticuerpo anti-humano de anexina a1. |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US11041019B2 (https=) |
| EP (1) | EP3579875B1 (https=) |
| JP (1) | JP7189142B2 (https=) |
| KR (1) | KR102687512B1 (https=) |
| CN (1) | CN110475570B (https=) |
| AU (1) | AU2018219595B2 (https=) |
| BR (1) | BR112019016160A2 (https=) |
| CA (1) | CA3052903C (https=) |
| ES (1) | ES3009440T3 (https=) |
| GB (1) | GB201702091D0 (https=) |
| IL (1) | IL268506A (https=) |
| MX (1) | MX2019009382A (https=) |
| RU (1) | RU2019126888A (https=) |
| WO (1) | WO2018146230A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2580241B1 (en) | 2010-06-09 | 2020-11-04 | Queen Mary & Westfield College, University of London | Annexin 1 antibody |
| GB201121564D0 (en) | 2011-12-14 | 2012-01-25 | Queen Mary & Westfield College | Use of antibody |
| EP3448874A4 (en) | 2016-04-29 | 2020-04-22 | Voyager Therapeutics, Inc. | COMPOSITIONS FOR TREATING A DISEASE |
| US11299751B2 (en) | 2016-04-29 | 2022-04-12 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
| GB201813137D0 (en) * | 2018-08-10 | 2018-09-26 | Medannex Ltd | Cancer treatment with an antibody |
| CA3138550A1 (en) | 2019-04-30 | 2020-11-05 | Target Discovery Merger Sub II, LLC | Cancer associated antibody compositions and methods of use |
| EP4061420A1 (en) * | 2019-11-20 | 2022-09-28 | Abvision, Inc. | Monoclonal antibodies that target human cd47 protein |
| CN118465272B (zh) * | 2019-12-04 | 2025-08-19 | 珠海泰诺麦博制药股份有限公司 | 抗人巨细胞病毒抗体及其用途 |
| US20240124606A1 (en) * | 2021-02-22 | 2024-04-18 | Northwestern University | Anti-cd73 monoclonal antibodies |
| CA3238416A1 (en) | 2021-11-18 | 2023-05-25 | Henry Charles Wilson HAYS | Combination therapy for cancer |
| WO2025149667A1 (en) | 2024-01-12 | 2025-07-17 | Pheon Therapeutics Ltd | Antibody drug conjugates and uses thereof |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8625941D0 (en) | 1986-10-30 | 1986-12-03 | Sandoz Ltd | Substituted alpha-amino acids |
| US5051364A (en) | 1989-02-16 | 1991-09-24 | The Salk Institute For Biological Studies | Anti-lipocortin-I and anti-lipocortin-II monoclonal antibodies |
| US5565338A (en) | 1990-06-04 | 1996-10-15 | La Jolla Institute For Allergy And Immunology | Suppressor T-cell hybridoma and production of allergen specific glycosylation inhibiting factor |
| US5462990A (en) | 1990-10-15 | 1995-10-31 | Board Of Regents, The University Of Texas System | Multifunctional organic polymers |
| AU2002364607A1 (en) | 2001-12-28 | 2003-07-24 | The Burnham Institute | Novel ligand involved in the transmigration of leukocytes . |
| WO2005019429A2 (en) | 2003-08-22 | 2005-03-03 | Potentia Pharmaceuticals, Inc. | Compositions and methods for enhancing phagocytosis or phagocyte activity |
| WO2005027965A1 (en) | 2003-09-24 | 2005-03-31 | Peter Krammer | Antibodies against annexins, use thereof for therapy and diagnosis. use of annexins for therapy and diagnosis. |
| CA2545166A1 (en) * | 2003-11-11 | 2005-05-19 | Chugai Seiyaku Kabushiki Kaisha | Humanized anti-cd47 antibody |
| JP5139058B2 (ja) | 2004-06-02 | 2013-02-06 | シドニー キンメル キャンサー センター | 新形成または新生脈管構造の検出、画像化および処置のための血管標的 |
| GB0822011D0 (en) | 2008-12-02 | 2009-01-07 | Queen Mary & Westfield College | Treatment |
| EP2580241B1 (en) * | 2010-06-09 | 2020-11-04 | Queen Mary & Westfield College, University of London | Annexin 1 antibody |
| CN102898527B (zh) | 2011-07-25 | 2016-12-21 | 三星电子株式会社 | 融合蛋白、药物组合物及预防或治疗癌症的方法 |
| GB201121561D0 (en) | 2011-12-14 | 2012-01-25 | Queen Mary & Westfield College | Transgenic animal |
| GB201121564D0 (en) | 2011-12-14 | 2012-01-25 | Queen Mary & Westfield College | Use of antibody |
| KR20150029457A (ko) | 2013-09-10 | 2015-03-18 | 삼성전자주식회사 | 아넥신 a1에 결합하는 폴리펩타이드 및 그의 용도 |
-
2017
- 2017-02-08 GB GBGB1702091.8A patent/GB201702091D0/en not_active Ceased
-
2018
- 2018-02-08 CN CN201880022875.8A patent/CN110475570B/zh active Active
- 2018-02-08 MX MX2019009382A patent/MX2019009382A/es unknown
- 2018-02-08 EP EP18707635.1A patent/EP3579875B1/en active Active
- 2018-02-08 AU AU2018219595A patent/AU2018219595B2/en active Active
- 2018-02-08 KR KR1020197026545A patent/KR102687512B1/ko active Active
- 2018-02-08 ES ES18707635T patent/ES3009440T3/es active Active
- 2018-02-08 BR BR112019016160-0A patent/BR112019016160A2/pt unknown
- 2018-02-08 US US16/484,286 patent/US11041019B2/en active Active
- 2018-02-08 CA CA3052903A patent/CA3052903C/en active Active
- 2018-02-08 JP JP2019543805A patent/JP7189142B2/ja active Active
- 2018-02-08 WO PCT/EP2018/053232 patent/WO2018146230A1/en not_active Ceased
- 2018-02-08 RU RU2019126888A patent/RU2019126888A/ru unknown
-
2019
- 2019-08-05 IL IL268506A patent/IL268506A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2020506715A (ja) | 2020-03-05 |
| NZ756971A (en) | 2023-11-24 |
| CA3052903A1 (en) | 2018-08-16 |
| CN110475570B (zh) | 2023-10-27 |
| KR102687512B1 (ko) | 2024-07-22 |
| AU2018219595B2 (en) | 2024-08-08 |
| WO2018146230A1 (en) | 2018-08-16 |
| RU2019126888A3 (https=) | 2021-04-26 |
| BR112019016160A2 (pt) | 2020-03-24 |
| ES3009440T3 (en) | 2025-03-26 |
| EP3579875A1 (en) | 2019-12-18 |
| JP7189142B2 (ja) | 2022-12-13 |
| GB201702091D0 (en) | 2017-03-22 |
| EP3579875B1 (en) | 2025-01-22 |
| RU2019126888A (ru) | 2021-03-09 |
| IL268506A (en) | 2019-09-26 |
| US20200031911A1 (en) | 2020-01-30 |
| US11041019B2 (en) | 2021-06-22 |
| EP3579875C0 (en) | 2025-01-22 |
| CA3052903C (en) | 2024-07-02 |
| AU2018219595A1 (en) | 2019-09-26 |
| CN110475570A (zh) | 2019-11-19 |
| KR20190117009A (ko) | 2019-10-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2019009382A (es) | Anticuerpo anti-humano de anexina a1. | |
| MY198942A (en) | Anti-tau antibodies and methods of use | |
| BR112022009317A2 (pt) | Anticorpos de cd73 biparatópicos | |
| ZA202109042B (en) | Methods of reducing serum levels of fc-containing agents using fcrn antagonists | |
| NZ721678A (en) | Antibody molecules to pd-1 and uses thereof | |
| MX2020006508A (es) | Moleculas de union a antigeno biespecificas que se unen al receptor de leptina y/o gp130, y metodos para el uso de estas. | |
| EA033433B1 (ru) | Антитела к tau и их применение | |
| PH12018502451A1 (en) | Brain delivery protein | |
| PH12018502574A1 (en) | ANTI-IgE ANTIBODIES | |
| EP4241852A3 (en) | Antibody binding to fcrn for treating autoimmune diseases | |
| HRP20200572T1 (hr) | Anti-pvrig antitijela i postupci uporabe | |
| HRP20210096T1 (hr) | Novi oblik il33, mutirani oblici il33, protutijela, testovi i postupci njegove upotrebe | |
| RU2014153099A (ru) | Терапевтическое средство или профилактическое средство против деменции | |
| MX2012000316A (es) | Anticuerpos humanizados para el receptor 2 tipo toll y usos de los mismos. | |
| HRP20200174T1 (hr) | Antitijela antigena 2 anti-krvne dendritične stanice i njihova uporaba | |
| EA201691782A1 (ru) | Антитела, специфические к рецептору инсулиноподобного фактора роста 1, и их применения | |
| ECSP16070447A (es) | Moleculas de anticuerpo para tim-3 y sus usos | |
| WO2013011076A3 (en) | Tnf -alpha antigen- binding proteins with increased fcrn binding | |
| MX2017015811A (es) | Tratamiento de cancer por bloqueo combinado de las trayectorias de señalizacion de muerte programada 1 (pd)-1 y receptor 4 de quimiocina c-x-c(cxcr4). | |
| RU2016151265A (ru) | Антитела, направленные на cd127 | |
| EA201691779A1 (ru) | Антитела, специфические к рецептору инсулиноподобного фактора роста 1, и их применения | |
| WO2017083451A8 (en) | Binding molecules specific for asct2 and uses thereof | |
| MX371412B (es) | ANTICUERPOS BIESPECÍFICOS QUE SE UNEN ESPECÍFICAMENTE A LOXL2 Y ccl.2, COMPOSICIONES DE LOS MISMOS, Y SU USO EN EL TRATAMIENTO DE ESCLERODERMIA. | |
| JP2017534296A5 (https=) | ||
| EP4356972A3 (en) | Anti-annexin a2 monoclonal antibodies |